S&P 500 7,628.29 â–ŧ 57.85 (-0.75%) DOW 52,759.94 â–ŧ 425.96 (-0.80%) NASDAQ 26,096.35 â–ŧ 274.54 (-1.04%) US Markets Closed â€ĸ 12:02 AM ET

TVRD

Tvardi Therapeutics, Inc.

Price Chart
Latest Quote

$1.75

-0.05 (-3.06%)
Current Price
Previous Close $1.80
Open $1.81
Day High $1.84
Day Low $1.75
Volume 95,289
Fetched: 2026-09-02T04:02:02
Stock Information
Shares Outstanding 13.34M
Total Debt $145K
Cash Equivalents $15.77M
Net Income $-26.06M
Sector Healthcare
Industry Biotechnology
Market Cap $23.28M
EPS (TTM) $-2.80
Exchange NCM
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$7.66M
Income$-26.06M
Book/sh$1.55
Cash/sh$1.18
Employees12
Financial Ratios
Quick Ratio1.73
Current Ratio1.87
Debt/Eq1.73
Returns & Margins
ROA-55.51%
ROE-126.19%
Ownership
Insider Ownership24.36%
Institutional Ownership17.34%
Insider & Institutional transactions data not available
Valuation Ratios
Forward P/E-0.74
P/B1.13
Analyst Data
Recommendationbuy
Target Price$8.50
Technical Indicators
SMA20$1.84
SMA50$2.31
SMA200$3.37
RSI47.71
ATR0.1091
Shares Float9.63M
Short Float1.30%
Short Ratio0.28
Rel Volume0.50
Performance History
Week-1.97%
Month-16.90%
Quarter-45.81%
6 Months-55.93%
YTD-57.23%
Year-94.24%
3 Years-98.30%
5 Years-99.66%
10 Years-99.09%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-09-01 $1.75 96,000
2026-08-31 $1.80 117,400
2026-08-27 $1.80 70,900
2026-08-26 $1.78 87,500
2026-08-25 $1.82 77,100
2026-08-24 $1.78 63,400
2026-08-21 $1.86 166,800
2026-08-20 $1.83 126,100
2026-08-19 $1.88 201,900
2026-08-18 $1.90 100,500
2026-08-17 $1.86 213,600
2026-08-14 $1.90 355,700
2026-08-13 $1.77 130,200
2026-08-12 $1.77 98,700
2026-08-11 $1.77 183,700
2026-08-10 $1.76 390,000
2026-08-07 $1.87 103,700
2026-08-06 $1.85 519,900
2026-08-05 $2.00 335,400
2026-08-04 $2.03 393,500
2026-08-03 $2.02 216,200
About Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

📰 Latest News
TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know
Zacks â€ĸ 2026-07-09T14:52:00Z
Article thumbnail
Sector Update: Healthcare Stocks Lower Wednesday Afternoon
MT Newswires â€ĸ 2026-07-08T17:48:15Z
Top Midday Gainers
MT Newswires â€ĸ 2026-07-08T17:26:02Z
Sector Update: Health Care Stocks Fall Late Afternoon
MT Newswires â€ĸ 2026-04-20T19:55:23Z
We're Keeping An Eye On Tvardi Therapeutics' (NASDAQ:TVRD) Cash Burn Rate
Simply Wall St. â€ĸ 2026-02-07T13:48:02Z
Article thumbnail
Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Zacks â€ĸ 2025-11-18T14:55:02Z
Article thumbnail
Tvardi: Q3 Earnings Snapshot
Associated Press Finance â€ĸ 2025-11-13T21:08:55Z
Here's Why Tvardi (TVRD) Is a Great 'Buy the Bottom' Stock Now
Zacks â€ĸ 2025-10-28T13:55:02Z
Article thumbnail
Down 83.0% in 4 Weeks, Here's Why Tvardi (TVRD) Looks Ripe for a Turnaround
Zacks â€ĸ 2025-10-16T13:35:02Z
Article thumbnail
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
Zacks â€ĸ 2025-10-14T15:24:00Z
Article thumbnail
Period:
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Total Revenue $0 $0 $0 $0
Operating Revenue $0 $0 $0 $0
Expenses
Total Expenses $26,748,000 $28,107,000 $18,665,000 $21,193,000
Other Income Expense $7,159,000 $-2,037,000 - -
Other Non Operating Income Expenses $7,159,000 $-2,037,000 - -
Net Non Operating Interest Income Expense $1,375,000 $747,000 $1,318,000 $651,000
Operating Expense $26,748,000 $28,107,000 $18,665,000 $21,193,000
General And Administrative Expense $8,737,000 $4,457,000 $2,799,000 $2,727,000
Interest Expense - - $0 $3,000
Interest Expense Non Operating - - $0 $3,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-18,214,000 $-29,397,000 $-17,347,000 $-20,542,000
Net Interest Income $1,375,000 $747,000 $1,318,000 $651,000
Interest Income $1,375,000 $747,000 $1,318,000 $654,000
Normalized Income $-18,214,000 $-29,397,000 $-17,347,000 $-20,542,000
Net Income From Continuing And Discontinued Operation $-18,214,000 $-29,397,000 $-17,347,000 $-20,542,000
Total Operating Income As Reported $-26,748,000 $-28,107,000 $-18,665,000 $-21,193,000
Net Income Common Stockholders $-18,214,000 $-29,397,000 $-17,347,000 $-20,542,000
Net Income $-18,214,000 $-29,397,000 $-17,347,000 $-20,542,000
Net Income Including Noncontrolling Interests $-18,214,000 $-29,397,000 $-17,347,000 $-20,542,000
Net Income Continuous Operations $-18,214,000 $-29,397,000 $-17,347,000 $-20,542,000
Pretax Income $-18,214,000 $-29,397,000 $-17,347,000 $-20,542,000
Interest Income Non Operating $1,375,000 $747,000 $1,318,000 $654,000
Operating Income $-26,748,000 $-28,107,000 $-18,665,000 $-21,193,000
Per Share
Diluted EPS $-3.26 $-11.41 $-6.74 $-7.98
Basic EPS $-2.46 $-11.41 $-6.74 $-7.98
Other
Tax Effect Of Unusual Items $0 $0 $0 $0
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-26,653,000 $-28,012,000 $-17,252,000 $-20,454,000
Reconciled Depreciation $95,000 $95,000 $95,000 $85,000
EBITDA (Bullshit earnings) $-26,653,000 $-28,012,000 $-17,252,000 $-20,454,000
EBIT $-26,748,000 $-28,107,000 $-17,347,000 $-20,539,000
Diluted Average Shares $7,783,182 $2,575,462 $2,575,462 $2,575,462
Basic Average Shares $7,404,065 $2,575,462 $2,575,462 $2,575,462
Diluted NI Availto Com Stockholders $-18,214,000 $-29,397,000 $-17,347,000 $-20,542,000
Research And Development $18,011,000 $23,650,000 $15,866,000 $18,466,000
Selling General And Administration $8,737,000 $4,457,000 $2,799,000 $2,727,000
Other Gand A $8,737,000 $4,457,000 $2,799,000 $2,727,000
Fetched: 2026-08-19
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $20,624,000 $-91,516,000 $-62,506,000 $-45,562,000
Total Assets $32,073,000 $35,199,000 $27,001,000 $45,097,000
Total Non Current Assets $535,000 $3,513,000 $843,000 $988,000
Other Non Current Assets $17,000 $17,000 $17,000 $17,000
Non Current Deferred Assets $0 $2,811,000 - -
Goodwill And Other Intangible Assets $322,000 $385,000 $448,000 $511,000
Other Intangible Assets $322,000 $385,000 $448,000 $511,000
Current Assets $31,538,000 $31,686,000 $26,158,000 $44,109,000
Prepaid Assets $727,000 $72,000 $3,239,000 $370,000
Cash Cash Equivalents And Short Term Investments $30,811,000 $31,614,000 $22,919,000 $43,739,000
Cash And Cash Equivalents $20,734,000 $31,614,000 $22,919,000 $21,489,000
Debt
Total Debt $201,000 $30,563,000 $368,000 $450,000
Long Term Debt And Capital Lease Obligation $85,000 $30,460,000 $275,000 $368,000
Current Debt And Capital Lease Obligation $116,000 $103,000 $93,000 $82,000
Long Term Debt - $30,259,000 - -
Liabilities
Total Liabilities Net Minority Interest $11,127,000 $126,330,000 $89,059,000 $90,148,000
Total Non Current Liabilities Net Minority Interest $85,000 $115,963,000 $85,778,000 $85,871,000
Current Liabilities $11,042,000 $10,367,000 $3,281,000 $4,277,000
Payables And Accrued Expenses $9,629,000 $9,122,000 $2,246,000 $3,517,000
Payables $3,219,000 $2,186,000 $1,611,000 $2,409,000
Accounts Payable $3,219,000 $2,186,000 $1,611,000 $2,409,000
Equity
Common Stock Equity $20,946,000 $-91,131,000 $-62,058,000 $-45,051,000
Total Equity Gross Minority Interest $20,946,000 $-91,131,000 $-62,058,000 $-45,051,000
Stockholders Equity $20,946,000 $-91,131,000 $-62,058,000 $-45,051,000
Gains Losses Not Affecting Retained Earnings $8,000 $0 $0 $-24,000
Other Equity Adjustments $8,000 - - $-24,000
Retained Earnings $-110,450,000 $-92,236,000 $-62,839,000 $-45,492,000
Preferred Securities Outside Stock Equity $0 $85,503,000 $85,503,000 $85,503,000
Other
Ordinary Shares Number $9,381,344 $9,355,542 $9,355,542 $9,355,542
Share Issued $9,381,344 $9,355,542 $9,355,542 $9,355,542
Tangible Book Value $20,624,000 $-91,516,000 $-62,506,000 $-45,562,000
Invested Capital $20,946,000 $-60,872,000 $-62,058,000 $-45,051,000
Working Capital $20,496,000 $21,319,000 $22,877,000 $39,832,000
Capital Lease Obligations $201,000 $304,000 $368,000 $450,000
Total Capitalization $20,946,000 $-60,872,000 $-62,058,000 $-45,051,000
Additional Paid In Capital $131,379,000 $1,103,000 $762,000 $446,000
Capital Stock $9,000 $2,000 $19,000 $19,000
Common Stock $9,000 $2,000 $19,000 $19,000
Long Term Capital Lease Obligation $85,000 $201,000 $275,000 $368,000
Current Capital Lease Obligation $116,000 $103,000 $93,000 $82,000
Pensionand Other Post Retirement Benefit Plans Current $1,297,000 $1,142,000 $942,000 $678,000
Current Accrued Expenses $6,410,000 $6,936,000 $635,000 $1,108,000
Net PPE $196,000 $300,000 $378,000 $460,000
Gross PPE $196,000 $300,000 $378,000 $460,000
Other Properties $196,000 $300,000 $378,000 $460,000
Other Short Term Investments $10,077,000 $0 $0 $22,250,000
Fetched: 2026-08-19
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $-23,499,000 $-18,305,000 $-21,040,000 $-17,916,000
Operating Activities
Operating Cash Flow $-23,499,000 $-18,305,000 $-21,040,000 $-17,866,000
Cash Flow From Continuing Operating Activities $-23,499,000 $-18,305,000 $-21,040,000 $-17,866,000
Investing Activities
Investing Cash Flow $-10,084,000 $0 $22,468,000 $-22,000,000
Cash Flow From Continuing Investing Activities $-10,084,000 $0 $22,468,000 $-22,000,000
Capital Expenditure - - - $-50,000
Financing Activities
Issuance Of Capital Stock $532,000 $5,000 $2,000 $4,000
Financing Cash Flow $22,703,000 $27,000,000 $2,000 $4,000
Cash Flow From Continuing Financing Activities $22,703,000 $27,000,000 $2,000 $4,000
Net Other Financing Charges $22,171,000 $-1,303,000 - -
Net Common Stock Issuance $532,000 $5,000 $2,000 $4,000
Common Stock Issuance $532,000 $5,000 $2,000 $4,000
Other
Issuance Of Debt $0 $28,298,000 - -
End Cash Position $20,734,000 $31,614,000 $22,919,000 $21,489,000
Beginning Cash Position $31,614,000 $22,919,000 $21,489,000 $61,351,000
Changes In Cash $-10,880,000 $8,695,000 $1,430,000 $-39,862,000
Net Issuance Payments Of Debt $0 $28,298,000 - -
Net Long Term Debt Issuance $0 $28,298,000 - -
Long Term Debt Issuance $0 $28,298,000 - -
Net Investment Purchase And Sale $-10,084,000 $0 $22,468,000 $-21,950,000
Sale Of Investment $21,402,000 $0 $22,468,000 $22,045,000
Purchase Of Investment $-31,486,000 $0 $0 $-43,995,000
Change In Working Capital $508,000 $8,641,000 $-3,959,000 $2,666,000
Change In Other Current Liabilities $-103,000 $-93,000 $-82,000 $-7,000
Change In Payables And Accrued Expense $919,000 $5,567,000 $-1,008,000 $2,195,000
Change In Prepaid Assets $-308,000 $3,167,000 $-2,869,000 $478,000
Other Non Cash Items $723,000 $230,000 $51,000 $34,000
Stock Based Compensation $1,399,000 $319,000 $314,000 $246,000
Unrealized Gain Loss On Investment Securities $-7,810,000 $1,807,000 - -
Amortization Of Securities $-200,000 $0 $-194,000 $-355,000
Depreciation Amortization Depletion $95,000 $95,000 $95,000 $85,000
Depreciation And Amortization $95,000 $95,000 $95,000 $85,000
Net Income From Continuing Operations $-18,214,000 $-29,397,000 $-17,347,000 $-20,542,000
Net PPE Purchase And Sale - - $0 $-50,000
Purchase Of PPE - - $0 $-50,000
Fetched: 2026-08-19